TaiRx

TaiRx ROE

The Return on Equity (ROE) of TaiRx (6580.TWO) as of Nov 16, 2026 is -50.08 %. In the previous year, Return on Equity (ROE) was -21.45 % — a change of 133.42% (lower).

ROE

-50.08 %

YoY

133.42%

Last updated:

In 2025, TaiRx's return on equity (ROE) was -50.08 %, a 133.42% increase from the -21.45 % ROE in the previous year.

The TaiRx ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-35.52 TWD
Jan 1, 2019
-48.26 TWD
Jan 1, 2020
-20.21 TWD
Jan 1, 2021
-18.62 TWD
Jan 1, 2022
-44.28 TWD
Jan 1, 2023
-27.51 TWD
Jan 1, 2024
-21.45 TWD
Jan 1, 2025
-50.08 TWD
The TaiRx ROE history
YEARROEYoY
-50.08 %+133.42%
-21.45 %-22.01%
-27.51 %-37.88%
-44.28 %+137.80%
-18.62 %-7.85%
-20.21 %-58.12%
-48.26 %+35.87%
-35.52 %+117.12%
-16.36 %+26.44%
-12.94 %+11.43%
-11.61 %+8.24%
-10.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx, Inc. generates revenue through the sale of its drug products, primarily targeting domestic medical institutions in Taipei. The company's commercialized drug Zelnite is distributed via distributors to medical facilities at all levels, while its pipeline includes CVM-1118 and Rexis, which are in clinical trials. The firm focuses on developing cancer treatment drugs and sepsis adjuvant therapy drugs, with TRX-NOC, TRX-920, TRX-711, and TRX-105 forming part of its product portfolio. Revenue streams derive from both current sales of Zelnite and future potential from clinical-stage products. TaiRx's primary customers are domestic medical institutions across Taipei, which purchase Zelnite through established distributor networks. The company's R&D efforts concentrate on advancing cancer therapeutics and sepsis treatments, with CVM-1118 and Rexis representing key pipeline assets currently undergoing clinical evaluation. The firm maintains a portfolio of drug candidates including TRX-NOC, TRX-920, TRX-711, and TRX-105, though these are not yet commercially available. The company's business model centers on developing novel drug products for cancer treatment and sepsis adjuvant therapy, with Zelnite being the only product currently sold to medical institutions. Clinical-stage products CVM-1118 and Rexis are in development, while TRX-NOC, TRX-920, TRX-711, and TRX-105 represent additional pipeline candidates. Revenue is derived from Zelnite sales through distributors, with future potential from the clinical-stage pipeline. TaiRx is one of the most popular companies on Eulerpool.

ROE Details

Decoding TaiRx's Return on Equity (ROE)

TaiRx's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing TaiRx's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

TaiRx's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in TaiRx’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about TaiRx stock

Return on Equity (ROE) of TaiRx is -50.08 % in 2025.

Return on Equity (ROE) of TaiRx changed from -21.45 % to -50.08 %, representing a 133.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) TaiRx since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s TaiRx with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — TaiRx

All Key Metrics — TaiRx